Works matching IS 10600280 AND DT 2024 AND VI 58 AND IP 4
Results: 15
Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 444, doi. 10.1177/10600280231224039
- By:
- Publication type:
- Article
Reply: Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 446, doi. 10.1177/10600280231224021
- By:
- Publication type:
- Article
Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 391, doi. 10.1177/10600280231190401
- By:
- Publication type:
- Article
Incretin Analogs for Weight Management in Adults Without Diabetes.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 398, doi. 10.1177/10600280231190089
- By:
- Publication type:
- Article
A Real-World Disproportionality Analysis of Drug-Induced Immune Hemolytic Anemia in the FDA Adverse Event Reporting System.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 375, doi. 10.1177/10600280231189897
- By:
- Publication type:
- Article
Daptomycin Plus Oxacillin for Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 360, doi. 10.1177/10600280231189888
- By:
- Publication type:
- Article
Risk Stratification for Supratherapeutic Peak Anti-Xa Levels in Adult Patients on Therapeutic Enoxaparin.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 366, doi. 10.1177/10600280231189488
- By:
- Publication type:
- Article
Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 349, doi. 10.1177/10600280231188171
- By:
- Publication type:
- Article
Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 407, doi. 10.1177/10600280231187421
- By:
- Publication type:
- Article
Pharmacist Prescribing Models for HIV Pre-exposure and Post-exposure Prophylaxis.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 434, doi. 10.1177/10600280231187171
- By:
- Publication type:
- Article
Authors Reply to Comment on Rotshild et al's "The Risk for Prostate Cancer With Calcium Channel Blockers".
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 443, doi. 10.1177/10600280231185784
- By:
- Publication type:
- Article
Comment on Rotshild et al's "The Risk for Prostate Cancer With Calcium Channel Blockers".
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 441, doi. 10.1177/10600280231185781
- By:
- Publication type:
- Article
Association of Argatroban Dose With Coagulation Laboratory Test in Patients on Extracorporeal Membrane Oxygenation: Activated Clotting Time vs Activated Partial Thromboplastin Time.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 383, doi. 10.1177/10600280231183510
- By:
- Publication type:
- Article
A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 428, doi. 10.1177/10600280231182421
- By:
- Publication type:
- Article
Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.
- Published in:
- Annals of Pharmacotherapy, 2024, v. 58, n. 4, p. 416, doi. 10.1177/10600280231153863
- By:
- Publication type:
- Article